Department of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Cancer Center Amsterdam, Amsterdam, The Netherlands.
Surg Endosc. 2023 Apr;37(4):2659-2672. doi: 10.1007/s00464-022-09735-4. Epub 2022 Nov 18.
Many centers worldwide are shifting from laparoscopic to robotic minimally invasive hepato-pancreato-biliary resections (MIS-HPB) but large single center series assessing this process are lacking. We hypothesized that the introduction of robot-assisted surgery was safe and feasible in a high-volume center.
Single center, post-hoc assessment of prospectively collected data including all consecutive MIS-HPB resections (January 2010-February 2022). As of December 2018, all MIS pancreatoduodenectomy and liver resections were robot-assisted. All surgeons had participated in dedicated training programs for laparoscopic and robotic MIS-HPB. Primary outcomes were in-hospital/30-day mortality and Clavien-Dindo ≥ 3 complications.
Among 1875 pancreatic and liver resections, 600 (32%) were MIS-HPB resections. The overall rate of conversion was 4.3%, Clavien-Dindo ≥ 3 complications 25.7%, and in-hospital/30-day mortality 1.8% (n = 11). When comparing the period before and after the introduction of robotic MIS-HPB (Dec 2018), the overall use of MIS-HPB increased from 25.3 to 43.8% (P < 0.001) and blood loss decreased from 250 ml [IQR 100-500] to 150 ml [IQR 50-300] (P < 0.001). The 291 MIS pancreatic resections included 163 MIS pancreatoduodenectomies (52 laparoscopic, 111 robotic) with 4.3% conversion rate. The implementation of robotic pancreatoduodenectomy was associated with reduced operation time (450 vs 361 min; P < 0.001), reduced blood loss (350 vs 200 ml; P < 0.001), and a decreased rate of delayed gastric emptying (28.8% vs 9.9%; P = 0.009). The 309 MIS liver resections included 198 laparoscopic and 111 robotic procedures with a 3.6% conversion rate. The implementation of robotic liver resection was associated with less overall complications (24.7% vs 10.8%; P = 0.003) and shorter hospital stay (4 vs 3 days; P < 0.001).
The introduction of robotic surgery was associated with greater implementation of MIS-HPB in up to nearly half of all pancreatic and liver resections. Although mortality and major morbidity were not affected, robotic surgery was associated with improvements in some selected outcomes. Ultimately, randomized studies and high-quality registries should determine its added value.
全球许多中心正在从腹腔镜微创肝胰胆切除术(MIS-HPB)转向机器人手术,但缺乏大型单中心系列评估这一过程的研究。我们假设在高容量中心引入机器人辅助手术是安全可行的。
单中心、回顾性评估前瞻性收集的数据,包括所有连续的 MIS-HPB 切除术(2010 年 1 月至 2022 年 2 月)。截至 2018 年 12 月,所有 MIS 胰十二指肠切除术和肝切除术均为机器人辅助。所有外科医生均参加了专门的腹腔镜和机器人 MIS-HPB 培训计划。主要结局是住院/30 天死亡率和 Clavien-Dindo≥3 级并发症。
在 1875 例胰腺和肝脏切除术中,有 600 例(32%)为 MIS-HPB 切除术。总的转化率为 4.3%,Clavien-Dindo≥3 级并发症为 25.7%,住院/30 天死亡率为 1.8%(n=11)。在比较引入机器人 MIS-HPB 前后的时期(2018 年 12 月)时,MIS-HPB 的总体使用率从 25.3%增加到 43.8%(P<0.001),出血量从 250ml[IQR 100-500]减少到 150ml[IQR 50-300](P<0.001)。291 例 MIS 胰腺切除术包括 163 例 MIS 胰十二指肠切除术(52 例腹腔镜,111 例机器人),转化率为 4.3%。机器人胰十二指肠切除术的实施与手术时间缩短(450 分钟比 361 分钟;P<0.001)、出血量减少(350 毫升比 200 毫升;P<0.001)和胃排空延迟率降低(28.8%比 9.9%;P=0.009)有关。309 例 MIS 肝切除术包括 198 例腹腔镜和 111 例机器人手术,转化率为 3.6%。机器人肝切除术的实施与总体并发症减少(24.7%比 10.8%;P=0.003)和住院时间缩短(4 天比 3 天;P<0.001)有关。
机器人手术的引入与 MIS-HPB 在近一半的胰腺和肝脏切除术的应用增加有关。虽然死亡率和主要发病率没有受到影响,但机器人手术与某些选定结局的改善有关。最终,随机研究和高质量的登记处应该确定其附加价值。